200
Participants
Start Date
July 25, 2019
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
OBT076, a CD205-directed antibody-drug conjugate
Intravenous (IV) infusion of OBT076 every 3 weeks.
COMPLETED
Columbia University Medical Center, New York
RECRUITING
University General Hospital Attikon, Chaïdári
COMPLETED
University of Pittsburgh, Pittsburgh
RECRUITING
Hospital Universitario Fundacion Jimenez Diaz, Madrid
COMPLETED
Moffitt Cancer Center, Tampa
RECRUITING
University Hospital Marqués de Valdecilla, Santander
COMPLETED
University of Mississippi Medical Center, Jackson
COMPLETED
St. Elizabeth Healthcare, Edgewood
ACTIVE_NOT_RECRUITING
The State University of Iowa, Iowa City
COMPLETED
Mayo Clinic, Phoenix
COMPLETED
Quantum Santa Fe, Santa Fe
COMPLETED
Cedars-Sinai, Los Angeles
COMPLETED
UCLA, Santa Monica
RECRUITING
Institut Jules Bordet, Brussels
COMPLETED
AZ Groeninge, Kortrijk
RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
GHP Saint-Joseph, Paris
COMPLETED
Hopital Saint Antoine, Paris
RECRUITING
Hopital Saint Louis, Paris
RECRUITING
Centre Eugène Marquis, Rennes
RECRUITING
ICANS - Institut de cancérologie Strasbourg, Strasbourg
RECRUITING
Institut Gustave Roussy - IGR, Villejuif
COMPLETED
Metropolitan Hospital, Athens
RECRUITING
Sotiria General Hospital, Athens
RECRUITING
University General Hospital of Heraklion, Heraklion
COMPLETED
EuroMedica, Thessaloniki
RECRUITING
START Barcelona HM Nou Delfos, Barcelona
Lead Sponsor
Oxford BioTherapeutics Ltd
INDUSTRY